Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma

BACKGROUND: Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. MATERIALS AND METHODS: A descriptive analysis on 2 AE cost comparisons was conducted using patient-level data for the nivolumab-based the...

Descripción completa

Detalles Bibliográficos
Autores principales: McGregor, Bradley, Geynisman, Daniel M, Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T, Del Tejo, Viviana, Du, Ella X, Yang, Xiaoran, Sendhil, Selvam R, Betts, Keith A, Huo, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847521/
https://www.ncbi.nlm.nih.gov/pubmed/36124890
http://dx.doi.org/10.1093/oncolo/oyac186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847521/
https://www.ncbi.nlm.nih.gov/pubmed/36124890
http://dx.doi.org/10.1093/oncolo/oyac186

Ejemplares similares